Repisalud
Publicación
Artículo científico (JournalArticle)
NKG2C/ KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma
Background: Activating and inhibitory receptors of natural killer (NK) cells such as NKp, NKG2, or CLEC are highly relevant to cold tumors including glioblastoma (GBM). Here, we aimed to characterize the expression of these receptors in GBM to gain insight into their potential role as modulators of the intratumoral microenvironment. Methods: We performed a transcriptomic analysis of several NK receptors with a focus on the activating receptor encoded by KLRC2, NKG2C, among bulk and single-cell RNA sequencing GBM data sets. We also evaluated the effects of KLRC2-overexpressing GL261 cells in mice treated with or without programmed cell death protein-1 (PD-1) monoclonal antibody (mAb). Finally, we analyzed samples from two clinical trials evaluating PD-1 mAb effects in patients with GBM to determine the potential of NKG2C to serve as a biomarker of response. Results: We observed significant expression of several inhibitory NK receptors on GBM-infiltrating NK and T cells, which contrasts with the strong expression of KLRC2 on tumor cells, mainly at the infiltrative margin. Neoplastic KLRC2 expression was associated with a reduction in the number of myeloid-derived suppressor cells and with a higher level of tumor-resident lymphocytes. A stronger antitumor activity after PD-1 mAb treatment was observed in NKG2Chigh-expressing tumors both in mouse models and patients with GBM whereas the expression of inhibitory NK receptors showed an inverse association. Conclusions: This study explored the role of neoplastic NKG2C/KLRC2 expression in shaping the immune profile of GBM and suggests that it is a predictive biomarker for positive responses to immune checkpoint inhibitor treatment in patients with GBM. Future studies could further validate this finding in prospective trials.
Proyecto:
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20/00434
,
ES / RTC2019-006860-1 Not available
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI21/01406
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica PI22/01171
,
Instituto de Salud Carlos III / Técnica y de Innovación 2021-2023 PI21/01168
,
ES / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) 00002
,
ES / PI21CIII Not available
,
ES / TED2021-132318B-I00 BMD-7344
,
ES / P2022 00080
,
ES / CD21 00001
,
ES / CD22CIII 00116